Article

Sanofi, Novo, Lilly Shape up for Big Insulin Fight

Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.

Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.

Read the full story:

http://hcp.lv/KahW6a

Source: Reuters

Related Videos
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Elizabeth Grush, MBA
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Joseph Saseen, PharmD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Anna Mueller, MD, Mount Sinai
John Ostrominski, MD
Marc P. Bonaca, MD, MPH
Related Content
Rural health sign | Image credit: BJP7images - stock.adobe.com
April 15th 2025

FQHCs Show Low Engagement in Hypertension, Diabetes Trials

Pearl Steinzor
A new review finds federally qualified health centers (FQHCs) are underutilized in hypertension and type 2 diabetes clinical research, despite their potential to improve trial diversity.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com
April 15th 2025

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

Jared Kaltwasser
Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.
managed care cast logo
February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD
On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Center on Health Equity and Access
April 14th 2025

Health Equity & Access Weekly Roundup: April 14, 2025

Giuliana Grossi
From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
AI representation of housing stability | Image credit: GoldPumaze - stock.adobe.com
April 14th 2025

Housing Instability Linked to Worse Type 2 Diabetes Outcomes

Pearl Steinzor
New study finds adults with stable housing have slightly better blood sugar and blood pressure levels.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo